Cite
Dreyer TF, Kuhn S, Stange C, et al. The Chemokine CX3CL1 Improves Trastuzumab Efficacy in HER2 Low-Expressing Cancer . Cancer Immunol Res. 2021;9(7):779-789doi: 10.1158/2326-6066.CIR-20-0327.
Dreyer, T. F., Kuhn, S., Stange, C., Heithorst, N., Schilling, D., Jelsma, J., Sievert, W., Seitz, S., Stangl, S., Hapfelmeier, A., Noske, A., Wege, A. K., Weichert, W., Ruland, J., Schmitt, M., Dorn, J., Kiechle, M., Reuning, U., Magdolen, V., Multhoff, G., & Bronger, H. (2021). The Chemokine CX3CL1 Improves Trastuzumab Efficacy in HER2 Low-Expressing Cancer . Cancer immunology research, 9(7), 779-789. https://doi.org/10.1158/2326-6066.CIR-20-0327
Dreyer, Tobias F, et al. "The Chemokine CX3CL1 Improves Trastuzumab Efficacy in HER2 Low-Expressing Cancer ." Cancer immunology research vol. 9,7 (2021): 779-789. doi: https://doi.org/10.1158/2326-6066.CIR-20-0327
Dreyer TF, Kuhn S, Stange C, Heithorst N, Schilling D, Jelsma J, Sievert W, Seitz S, Stangl S, Hapfelmeier A, Noske A, Wege AK, Weichert W, Ruland J, Schmitt M, Dorn J, Kiechle M, Reuning U, Magdolen V, Multhoff G, Bronger H. The Chemokine CX3CL1 Improves Trastuzumab Efficacy in HER2 Low-Expressing Cancer . Cancer Immunol Res. 2021 Jul;9(7):779-789. doi: 10.1158/2326-6066.CIR-20-0327. Epub 2021 Apr 27. PMID: 33906866.
Copy
Download .nbib
